Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.

Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A.

Oncotarget. 2018 Nov 13;9(89):36048. doi: 10.18632/oncotarget.26373. eCollection 2018 Nov 13.

2.

BMPR2 inhibits activin and BMP signaling via wild-type ALK2.

Olsen OE, Sankar M, Elsaadi S, Hella H, Buene G, Darvekar SR, Misund K, Katagiri T, Knaus P, Holien T.

J Cell Sci. 2018 Jun 11;131(11). pii: jcs213512. doi: 10.1242/jcs.213512.

3.

Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo.

Holien T, Gederaas OA, Darvekar SR, Christensen E, Peng Q.

Lasers Surg Med. 2018 Jul;50(5):469-475. doi: 10.1002/lsm.22806. Epub 2018 Feb 20.

PMID:
29460964
4.

Artesunate shows potent anti-tumor activity in B-cell lymphoma.

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP.

J Hematol Oncol. 2018 Feb 20;11(1):23. doi: 10.1186/s13045-018-0561-0.

5.

Cytotoxic Effect on Human Myeloma Cells and Leukemic Cells by the Agaricus blazei Murill Based Mushroom Extract, Andosan™.

Tangen JM, Holien T, Mirlashari MR, Misund K, Hetland G.

Biomed Res Int. 2017;2017:2059825. doi: 10.1155/2017/2059825. Epub 2017 Nov 7.

6.

TGF-β contamination of purified recombinant GDF15.

Olsen OE, Skjærvik A, Størdal BF, Sundan A, Holien T.

PLoS One. 2017 Nov 21;12(11):e0187349. doi: 10.1371/journal.pone.0187349. eCollection 2017.

7.

Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A.

Haematologica. 2017 Jul;102(7):1266-1272. doi: 10.3324/haematol.2016.160564. Epub 2017 Apr 6.

8.

Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3.

Abdollahi P, Vandsemb EN, Hjort MA, Misund K, Holien T, Sponaas AM, Rø TB, Slørdahl TS, Børset M.

Mol Cancer Res. 2017 Jan;15(1):69-77. doi: 10.1158/1541-7786.MCR-16-0212. Epub 2016 Oct 3.

9.

Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.

Baranowska K, Misund K, Starheim KK, Holien T, Johansson I, Darvekar S, Buene G, Waage A, Bjørkøy G, Sundan A.

Oncotarget. 2016 Oct 25;7(43):70845-70856. doi: 10.18632/oncotarget.12226.

10.

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.

Starheim KK, Holien T, Misund K, Johansson I, Baranowska KA, Sponaas AM, Hella H, Buene G, Waage A, Sundan A, Bjørkøy G.

Blood Cancer J. 2016 Jul 15;6(7):e446. doi: 10.1038/bcj.2016.56.

11.

VOLIN and KJON-Two novel hyperdiploid myeloma cell lines.

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T.

Genes Chromosomes Cancer. 2016 Nov;55(11):890-901. doi: 10.1002/gcc.22388. Epub 2016 Jul 12.

PMID:
27311012
12.

Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.

Wang H, Teriete P, Hu A, Raveendra-Panickar D, Pendelton K, Lazo JS, Eiseman J, Holien T, Misund K, Oliynyk G, Arsenian-Henriksson M, Cosford ND, Sundan A, Prochownik EV.

Oncotarget. 2015 Oct 20;6(32):32380-95. doi: 10.18632/oncotarget.6116.

13.

Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.

Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T.

Haematologica. 2015 Dec;100(12):e511-4. doi: 10.3324/haematol.2015.124511. Epub 2015 Aug 20. No abstract available.

14.

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.

Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A.

Oncotarget. 2015 Sep 8;6(26):22698-705. Erratum in: Oncotarget. 2018 Nov 13;9(89):36048.

15.

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.

Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, Waage A, Sundan A, Holien T.

Cell Commun Signal. 2015 Jun 6;13:27. doi: 10.1186/s12964-015-0104-z.

16.

The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma.

Sponaas AM, Moen SH, Liabakk NB, Feyzi E, Holien T, Kvam S, Grøseth LA, Størdal B, Buene G, Espevik T, Waage A, Standal T, Sundan A.

Immun Inflamm Dis. 2015 Jun;3(2):94-102. doi: 10.1002/iid3.53. Epub 2015 Mar 2.

17.

Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.

Jung KY, Wang H, Teriete P, Yap JL, Chen L, Lanning ME, Hu A, Lambert LJ, Holien T, Sundan A, Cosford ND, Prochownik EV, Fletcher S.

J Med Chem. 2015 Apr 9;58(7):3002-24. doi: 10.1021/jm501440q. Epub 2015 Mar 30.

18.

The role of bone morphogenetic proteins in myeloma cell survival.

Holien T, Sundan A.

Cytokine Growth Factor Rev. 2014 Jun;25(3):343-50. doi: 10.1016/j.cytogfr.2014.04.009. Epub 2014 May 9. Review.

PMID:
24853340
19.

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T.

Blood Cancer J. 2014 Mar 21;4:e196. doi: 10.1038/bcj.2014.16.

20.

Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells.

Müller R, Misund K, Holien T, Bachke S, Gilljam KM, Våtsveen TK, Rø TB, Bellacchio E, Sundan A, Otterlei M.

PLoS One. 2013 Jul 31;8(7):e70430. doi: 10.1371/journal.pone.0070430. Print 2013.

21.

Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.

Holien T, Olsen OE, Misund K, Hella H, Waage A, Rø TB, Sundan A.

Eur J Haematol. 2013 Oct;91(4):339-46. doi: 10.1111/ejh.12176. Epub 2013 Aug 20.

PMID:
23869695
22.

HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.

Rø TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Børset M.

Exp Hematol. 2013 Jul;41(7):646-55. doi: 10.1016/j.exphem.2013.03.002. Epub 2013 Mar 14.

PMID:
23499762
23.

A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells.

Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, Børset M, Waage A, Sundan A.

J Biomol Screen. 2013 Jul;18(6):637-46. doi: 10.1177/1087057113478168. Epub 2013 Feb 27.

PMID:
23446700
24.

Oncogene addiction to c-MYC in myeloma cells.

Holien T, Sundan A.

Oncotarget. 2012 Aug;3(8):739-40. No abstract available.

25.

Addiction to c-MYC in multiple myeloma.

Holien T, Våtsveen TK, Hella H, Waage A, Sundan A.

Blood. 2012 Sep 20;120(12):2450-3. Epub 2012 Jul 17.

PMID:
22806891
26.

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.

Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Grøseth LA, Rekvig M, Børset M, Standal T, Waage A, Sundan A.

Leukemia. 2012 May;26(5):1073-80. doi: 10.1038/leu.2011.263. Epub 2011 Sep 23. Erratum in: Leukemia. 2012 May;26(5):1154.

PMID:
21941367
27.

Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.

Fagerli UM, Ullrich K, Stühmer T, Holien T, Köchert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD Jr, Mathas S, Sundan A, Bargou RC, Dörken B, Børset M, Janz M.

Oncogene. 2011 Jul 14;30(28):3198-206. doi: 10.1038/onc.2011.79. Epub 2011 Apr 11.

PMID:
21478911
28.

CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis.

Nørgaard NN, Holien T, Jönsson S, Hella H, Espevik T, Sundan A, Standal T.

J Immunol. 2010 Sep 15;185(6):3131-9. doi: 10.4049/jimmunol.0903605. Epub 2010 Aug 11.

29.

c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A.

Eur J Haematol. 2009 Apr;82(4):277-87. doi: 10.1111/j.1600-0609.2009.01212.x. Epub 2009 Jan 6.

30.

Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.

Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M.

Blood. 2008 Jan 15;111(2):806-15. Epub 2007 Oct 12.

31.

Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6.

Munthe E, Rian E, Holien T, Rasmussen A, Levy FO, Aasheim H.

FEBS Lett. 2000 Jan 21;466(1):169-74.

Supplemental Content

Loading ...
Support Center